Medication Guide App

Paclitaxel

Pronunciation

Class: Antineoplastic Agents
VA Class: AN900
Chemical Name: [2aR - [2aα,4β,4aβ,6β,9α(αR*,βS*),11α,1 - 2α,12aα,12bα]] - β - (Benzoylamino) - α - hydroxybenzenepropanoic acid 6, 12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a-,12b-dodecahydro-4, 11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz [1,2-b]oxet -9-yl ester
Molecular Formula: C47H51NO14
CAS Number: 33069-62-4
Brands: Abraxane, Onxol, formerly available as Taxol

Warning(s)

  • Conventional paclitaxel: Anaphylaxis and severe hypersensitivity reactions (dyspnea and hypotension requiring treatment, angioedema, and/or generalized urticaria) reported.1 Fatal reactions reported despite premedication.1 Administer premedication (corticosteroids, diphenhydramine, histamine H2-receptor antagonists) to all patients.1 Do not administer paclitaxel to patients with a history of severe hypersensitivity reactions to the drug.1

  • Paclitaxel should not be administered to patients with solid tumors with baseline ANC <1500/mm3 or to patients with AIDS-related Kaposi’s sarcoma with baseline ANC <1000/mm3.1 354 Monitor blood cell counts frequently.1 354

  • Albumin-bound paclitaxel differs from conventional paclitaxel; do not substitute albumin-bound paclitaxel for conventional paclitaxel or vice versa.354

  • Administer only under the supervision of qualified clinicians experienced in the use of cytotoxic therapy.1 Adequate diagnostic and treatment facilities should be readily available to manage complications.1

Introduction

Antineoplastic agent; natural or semisynthetic diterpene from the bark of the Western (Pacific) yew (Taxus brevifolia) or needles and twigs of Taxus baccata.1 2 3 4 6 7 20 22 71 183

Uses for Paclitaxel

Ovarian Cancer

Conventional paclitaxel: Treatment of advanced carcinoma of the ovary.1 24 26 28 29 122 124 129 130 131 132 134 135 136 178 183 184 239 240 241 242 249 Used as first-line therapy with carboplatin or cisplatin; this regimen is considered the treatment of choice for primary therapy of advanced ovarian cancer.122 133 134 135 136 178 Used alone or in combination therapy as second-line (salvage) therapy or subsequent therapy in patients with advanced ovarian epithelial cancer.1 124 134 241 242 247 302 303

Breast Cancer

Conventional paclitaxel: Adjuvant therapy in patients with evidence of axillary node tumor involvement; administered sequentially to standard doxorubicin-containing combination therapy.1 122 215

Slideshow: The Ferocity of Chemotherapy - Does The End Justify The Means?

Conventional paclitaxel: Treatment of breast cancer in patients who have metastatic disease refractory to combination chemotherapy or who have experienced relapse within 6 months of adjuvant chemotherapy; prior therapy should have included an anthracycline antineoplastic agent (e.g., doxorubicin) unless clinically contraindicated.1 36 37 42 43 45 46 122 215 352

Conventional paclitaxel: Treatment of breast cancer in combination with trastuzumab for tumors that overexpress the HER2 protein.122 215 244 307 308

Albumin-bound paclitaxel: Used alone for the treatment of breast cancer in patients who have metastatic disease refractory to conventional combination chemotherapy or who have experienced relapse within 6 months of adjuvant therapy; prior therapy should have included an anthracycline antineoplastic agent (e.g., doxorubicin) unless clinically contraindicated.215 354 355

Non-small Cell Lung Cancer (NSCLC)

Conventional paclitaxel: First-line treatment of advanced NSCLC in combination with carboplatin or cisplatin in patients for whom potentially curative surgery and/or radiation therapy are not possible.1 122 217 291

Albumin-bound paclitaxel: First-line treatment of advanced NSCLC in combination with carboplatin in patients for whom potentially curative surgery or radiation therapy is not possible.354 358 360

Conventional paclitaxel: Adjuvant therapy in selected patients with completely resected NSCLC; used in conjunction with a platinum agent (e.g., carboplatin).217 311

Small Cell Lung Cancer

Conventional paclitaxel: Active in the treatment of small cell lung carcinoma.97 98 106 107 108 122 227 228

AIDS-related Kaposi’s Sarcoma

Conventional paclitaxel: Second-line therapy for the palliative treatment of advanced or refractory AIDS-related Kaposi’s sarcoma1 116 117 118 119 120 121 122 216 (designated an orphan drug by FDA for this use).139

Pancreatic Cancer

Albumin-bound paclitaxel: First-line therapy of metastatic adenocarcinoma of the pancreas in combination with gemcitabine.354 361

Esophageal Cancer

Conventional paclitaxel: Has been used for the treatment of esophageal cancer .110 111 113 122 231 321

Bladder Cancer

Conventional paclitaxel: Active in the treatment of transitional cell bladder cancer.168 232

Head and Neck Cancer

Conventional paclitaxel: Active in the treatment of advanced (metastatic or locally recurrent) squamous cell carcinoma of the head and neck.80 81 96 122 213 260 330

Cervical Cancer

Conventional paclitaxel: Active in the treatment of cervical cancer.122 271 273 274 275 279 280 335

Endometrial Cancer

Conventional paclitaxel: Has been used for the treatment of endometrial cancer.122 336 337 338 339 340 341 342

Paclitaxel Dosage and Administration

General

  • Consult specialized references for procedures for proper handling and disposal of antineoplastic drugs.

  • Conventional paclitaxel: Premedicate all patients before paclitaxel administration to prevent severe hypersensitivity reactions.1 21 22 Oral dexamethasone 20 mg (10 mg for HIV-infected patients) administered approximately 12 and 6 hours before paclitaxel as well as IV diphenhydramine hydrochloride (or similar antihistamine) 50 mg and either IV cimetidine hydrochloride (300 mg of cimetidine) or ranitidine hydrochloride (50 mg of ranitidine) administered 30–60 minutes before paclitaxel can be given.1 22

  • Albumin-bound paclitaxel: Premedication generally not required, but may be necessary in patients who experienced a hypersensitivity reaction during a previous course.354

Administration

IV Administration

Handle cautiously (by trained nonpregnant personnel); use protective equipment (e.g., gloves) and wash hands after removal of the gloves.1 354

Immediately treat accidental contact with skin by thoroughly washing with soap and water; immediately treat accidental contact with mucous membranes by thoroughly washing with water.1 354 Dyspnea, chest pain, ocular burning, sore throat, and nausea reported upon inhalation.1

Conventional Paclitaxel

For solution and drug compatibility information, see Compatibility under Stability.

Administer by IV infusion.1

Contact of undiluted paclitaxel for injection concentrate with plasticized polyvinyl chloride (PVC) equipment or devices used to prepare solutions for infusion is not recommended.1 Diethylhexyl phthalate (DEHP) can be leached from PVC containers.1

Diluted paclitaxel solutions preferably should be stored in glass or polypropylene containers or in plastic (polypropylene or polyolefin) bags and administered through polyethylene-lined administration sets.1

A hydrophilic, microporous inline filter with a pore size ≤0.22 mcm is necessary during administration.1 7 20 45 Use of filter devices such as IVEX-2 filters, which incorporate short inlet and outlet PVC-coated tubing, has not resulted in significant leaching of DEHP.1 45 195

Do not use a Chemo Dispensing Pen or similar device; these devices may cause the stopper to collapse and contaminate the solution (resulting in loss of sterility).1

Dilution of Conventional Paclitaxel

The concentrate for injection must be diluted prior to administration.1 20

Dilute in 0.9% sodium chloride injection, 5% dextrose injection, 5% dextrose and 0.9% sodium chloride injection, or 5% dextrose in Ringer’s injection to a final paclitaxel concentration of 0.3–1.2 mg/mL.1

Rate of Administration of Conventional Paclitaxel

Infuse appropriate dose IV over 3 or 24 hours, depending on the treatment regimen.1

Albumin-bound Paclitaxel

Administer by IV infusion; do not use inline filters.354

Reconstitution of Albumin-bound Paclitaxel

Add 20 mL of 0.9% sodium chloride injection to a vial containing 100 mg of paclitaxel lyophilized powder; slowly inject the diluent onto the inside wall of the vial.354 Allow the vial to sit for ≥5 minutes (to ensure wetting of cake/powder); then, gently swirl and/or invert vial for ≥2 minutes.354 Handle in such a manner to avoid foaming.354 Resulting preparation contains 5 mg/mL.354

Withdraw appropriate dose from vial and transfer to an empty sterile PVC IV bag.354 DEHP-free containers and administration sets not needed.354

Rate of Administration of Albumin-bound Paclitaxel

Infuse appropriate dose IV over 30 minutes.354 Limiting infusion duration to 30 minutes reduces risk of infusion-related reactions.354

Dosage

Consult manufacturer's labeling and published protocols for formulation-specific regimens and specific dosages, methods of administration, and administration sequence of other antineoplastic agents used in combination regimens.354 362

Adults

Ovarian Cancer
IV (Conventional Paclitaxel)

Previously untreated patients: 175 mg/m2 given over 3 hours followed by cisplatin 75 mg/m2 in repeated 3-week cycles.1 Alternatively, 135 mg/m2 given over 24 hours followed by cisplatin 75 mg/m2 in repeated 3-week cycles.1

Previously treated patients: 135 mg/m2 or 175 mg/m2 given over 3 hours in repeated 3-week cycles.1

Reduce dose by 20% for subsequent cycles in patients who experience severe neutropenia (ANC <500/mm3 for >7 days) or severe peripheral neuropathy.1

Breast Cancer
IV (Conventional Paclitaxel)

Adjuvant therapy: 175 mg/m2 given over 3 hours in repeated 3-week cycles for 4 cycles administered sequentially to doxorubicin-containing chemotherapy.1

Treatment after failure of initial therapy for metastatic disease or relapse within 6 months of adjuvant therapy: 175 mg/m2 given over 3 hours in repeated 3-week cycles.1

Reduce dose by 20% for subsequent cycles in patients who experience severe neutropenia (ANC <500/mm3 for >7 days) or severe peripheral neuropathy.1

IV (Albumin-bound Paclitaxel)

Treatment after failure of initial therapy for metastatic disease or relapse within 6 months of adjuvant therapy: 260 mg/m2 every 3 weeks.354

Reduce dose to 220 mg/m2 for subsequent cycles in patients who experience severe neutropenia (ANC <500/mm3 for >7 days) or severe sensory neuropathy.354 Reduce dose to 180 mg/m2 if severe neutropenia or severe sensory neuropathy recurs.354 For grade 3 sensory neuropathy, withhold therapy until resolution to grade 1 or 2; when therapy is resumed, reduce dose.354

Non-small Cell Lung Cancer (NSCLC)
IV (Conventional Paclitaxel)

135 mg/m2 given over 24 hours followed by cisplatin 75 mg/m2 in repeated 3-week cycles.1 254 Alternatively, 175 mg/m2 given over 3 hours followed by cisplatin 80 mg/m2 in repeated 3-week cycles has been used.234

Reduce dose by 20% for subsequent cycles in patients who experience severe neutropenia (ANC <500/mm3 for >7 days) or severe peripheral neuropathy.1

IV (Albumin-bound Paclitaxel)

100 mg/m2 given over 30 minutes on days 1, 8, and 15, followed by carboplatin (target AUC 6 mg/mL per minute) on day 1 of each 21-day cycle.354

Table 1. Dosage Modification for Toxicity in Patients Receiving Albumin-bound Paclitaxel and Carboplatin for NSCLC354

Toxicity

Episode

Albumin-bound Paclitaxel and Carboplatin Dosage Modification

Febrile neutropenia (ANC <500/mm3 with fever >38°C)

or

delay of next cycle by >7 days for ANC <1500/mm3

or

ANC <500/mm3 for >7 days

First

Withhold both drugs until ANC ≥1500/mm3 and platelets ≥100,000/mm3 on day 1 or ANC ≥500/mm3 and platelets ≥50,000/mm3 on day 8 or 15 of the cycle; upon resumption, permanently reduce albumin-bound paclitaxel dose to 75 mg/m2 and carboplatin target AUC to 4.5 mg/mL per minute

Second

Withhold both drugs until ANC ≥1500/mm3 and platelets ≥100,000/mm3 on day 1 or ANC ≥500/mm3 and platelets ≥50,000/mm3 on day 8 or 15 of the cycle; upon resumption, permanently reduce albumin-bound paclitaxel dose to 50 mg/m2 and carboplatin target AUC to 3 mg/mL per minute

Third

Discontinue both drugs

Thrombocytopenia (platelet count <50,000/mm3)

First

Withhold both drugs until ANC ≥1500/mm3 and platelets ≥100,000/mm3 on day 1 or ANC ≥500/mm3 and platelets ≥50,000/mm3 on day 8 or 15 of the cycle; upon resumption, permanently reduce albumin-bound paclitaxel dose to 75 mg/m2 and carboplatin target AUC to 4.5 mg/mL per minute

Second

Discontinue both drugs

Severe (grade 3 or 4) peripheral neuropathy

First

Withhold both drugs until neuropathy is grade 1 or less; upon resumption, permanently reduce albumin-bound paclitaxel dose to 75 mg/m2 and carboplatin target AUC to 4.5 mg/mL per minute

Second

Withhold both drugs until neuropathy is grade 1 or less; upon resumption, permanently reduce albumin-bound paclitaxel dose to 50 mg/m2 and carboplatin target AUC to 3 mg/mL per minute

Third

Discontinue both drugs

AIDS-related Kaposi’s Sarcoma
IV (Conventional Paclitaxel)

135 mg/m2 given over 3 hours in repeated 3-week cycles.1 Alternatively, 100 mg/m2 over 3 hours in repeated 2-weeks cycles.1 The regimen given every 3 weeks is more toxic than the regimen given every 2 weeks; patients with poor performance status have been treated with paclitaxel 100 mg/m2.1

Reduce dose by 20% for subsequent cycles in patients who experience severe neutropenia (ANC <500/mm3 for >7 days); initiate granulocyte colony stimulating factor (G-CSF) as indicated.1

Pancreatic Cancer
IV (Albumin-bound Paclitaxel)

125 mg/m2 given over 30–40 minutes followed by gemcitabine 1 g/m2 IV over 30–40 minutes on days 1, 8, and 15 of each 28-day cycle.354

When dosage modification is necessary, reduce dose of albumin-bound paclitaxel in decrements of 25 mg/m2 (i.e., 1 dose level) and gemcitabine in decrements of 200 mg/m2 (i.e., 1 dose level); however, if a dose of albumin-bound paclitaxel 75 mg/m2 or a dose of gemcitabine 600 mg/m2 requires further reduction, discontinue both drugs.354

Table 2. Dosage Modification for Hematologic Toxicity in Patients Receiving Albumin-bound Paclitaxel and Gemcitabine for Pancreatic Cancer354

Cycle Day and Cell Counts (cells/mm3)

Albumin-bound Paclitaxel and Gemcitabine Dosage Modification

Day 1:

ANC <1500 or platelet count <100,000

Delay start of cycle until recovery

Day 8:

ANC 500 to <1000 or platelet count 50,000 to <75,000

Reduce dose of both drugs by 1 dose level

ANC <500 or platelet count <50,000

Withhold day 8 dose of both drugs

Day 15 (when day 8 doses were reduced or given without modification):

ANC 500 to <1000 or platelet count 50,000 to <75,000

Reduce dose of both drugs by 1 dose level from day 8

ANC <500 or platelet count <50,000

Withhold day 15 dose of both drugs

Day 15 (when day 8 doses were withheld):

ANC ≥1000 or platelet count ≥75,000

Reduce dose of both drugs by 1 dose level from day 1

ANC 500 to <1000 or platelet count 50,000 to <75,000

Reduce dose of both drugs by 2 dose levels from day 1

ANC <500 or platelet count <50,000

Withhold day 15 dose of both drugs

Table 3. Dosage Modification for Other Toxicities in Patients Receiving Albumin-bound Paclitaxel and Gemcitabine for Pancreatic Cancer354

Toxicity

Albumin-bound Paclitaxel and Gemcitabine Dosage Modification

Febrile neutropenia (grade 3 or 4)

Withhold both drugs until fever resolves and ANC is ≥1500/mm3; upon resumption, reduce dose of both drugs by 1 dose level

Severe (grade 3 or 4) peripheral neuropathy

Withhold albumin-bound paclitaxel until neuropathy is grade 1 or less; upon resumption, reduce albumin-bound paclitaxel dose by 1 dose level. No gemcitabine dose reduction required

Dermatologic toxicity (grade 2 or 3)

Reduce dose of both drugs by 1 dose level. Discontinue both drugs if toxicity persists

GI toxicity (grade 3 mucositis or diarrhea)

Withhold both drugs until GI toxicity is grade 1 or less; upon resumption, reduce dose of both drugs by 1 dose level

Special Populations

Hepatic Impairment

Increased risk of toxicity, particularly grade 3 or 4 myelosuppression.1 354 Adjust dosage as follows and closely monitor patients.1 354

Ovarian Cancer
IV (Conventional Paclitaxel)

See Table 4 for recommended initial doses; base further dose reductions in subsequent courses on individual tolerance.1 362 Differences in criteria for bilirubin concentrations between the 3- and 24- hour infusions are due to differences in clinical trial design.1 362

Table 4. Recommended Initial Doses of Conventional Paclitaxel for Ovarian Cancer in Patients with Hepatic Impairment1362

Transaminase Concentration

Bilirubin Concentration

Recommended Initial Dose (for 3- or 24-Hour Infusion)

<2 times ULN

and

≤1.5 mg/dL

135 mg/m2 over 24 hours

2 to <10 times ULN

and

≤1.5 mg/dL

100 mg/m2 over 24 hours

<10 times ULN

and

1.6–7.5 mg/dL

50 mg/m2 over 24 hours

≥10 times ULN

or

>7.5 mg/dL

Not recommended

<10 times ULN

and

≤1.25 times ULN

175 mg/m2 over 3 hours

<10 times ULN

and

1.26–2 times ULN

135 mg/m2 over 3 hours

<10 times ULN

and

2.01–5 times ULN

90 mg/m2 over 3 hours

≥10 times ULN

or

>5 times ULN

Not recommended

Breast Cancer
IV (Conventional Paclitaxel)

See Table 5 for recommended initial doses; base further dose reductions in subsequent courses on individual tolerance.1

Table 5. Recommended Initial Doses of Conventional Paclitaxel for Breast Cancer in Patients with Hepatic Impairment1362

Transaminase Concentration

Bilirubin Concentration

Recommended Initial Dose (for 3-Hour Infusion)

<10 times ULN

and

≤1.25 times ULN

175 mg/m2

<10 times ULN

and

1.26–2 times ULN

135 mg/m2

<10 times ULN

and

2.01–5 times ULN

90 mg/m2

≥10 times ULN

or

>5 times ULN

Not recommended

IV (Albumin-bound Paclitaxel)

See Table 6 for recommended initial doses; base further dose reductions in subsequent courses on individual tolerance.354

Table 6. Recommended Initial Doses of Albumin-bound Paclitaxel for Breast Cancer in Patients with Hepatic Impairment354

AST Concentration

Bilirubin Concentration

Recommended Initial Dose (for 30-Minute Infusion)

<10 times ULN

and

≤1.25 times ULN

260 mg/m2

<10 times ULN

and

1.26–2 times ULN

200 mg/m2

<10 times ULN

and

2.01–5 times ULN

130 mg/m2; may increase to 200 mg/m2 in subsequent courses based on tolerance

>10 times ULN

or

>5 times ULN

Not recommended

Non-small Cell Lung Cancer (NSCLC)
IV (Conventional Paclitaxel)

See Table 7 for recommended initial doses; base further dose reductions in subsequent courses on individual tolerance.1

Table 7. Recommended Initial Doses of Conventional Paclitaxel for NSCLC in Patients with Hepatic Impairment1362

Transaminase Concentration

Bilirubin Concentration

Recommended Initial Dose (for 24-Hour Infusion)

<2 times ULN

and

≤1.5 times ULN

135 mg/m2

2 to <10 times ULN

and

≤1.5 times ULN

100 mg/m2

<10 times ULN

and

1.6–7.5 times ULN

50 mg/m2

≥10 times ULN

or

>7.5 times ULN

Not recommended

IV (Albumin-bound Paclitaxel)

Patients with serum bilirubin concentrations exceeding the ULN were excluded from clinical studies of albumin-bound paclitaxel for NSCLC.354

See Table 8 for recommended initial doses; base further dose reductions in subsequent courses on individual tolerance.354

Table 8. Recommended Initial Doses of Albumin-bound Paclitaxel for NSCLC in Patients with Hepatic Impairment354

AST Concentration

Bilirubin Concentration

Recommended Initial Dose (for 30-Minute Infusion)

<10 times ULN

and

≤1.25 times ULN

100 mg/m2

<10 times ULN

and

1.26–2 times ULN

75 mg/m2

<10 times ULN

and

2.01–5 times ULN

50 mg/m2

>10 times ULN

or

>5 times ULN

Not recommended

AIDS-related Kaposi’s Sarcoma
IV (Conventional Paclitaxel)

Data not available to make dosage recommendations.1

Pancreatic Cancer
IV (Albumin-bound Paclitaxel)

Patients with serum bilirubin concentrations exceeding the ULN were excluded from clinical studies in pancreatic cancer.354

If AST <10 times ULN and bilirubin ≤1.25 times ULN, give usual initial dose of 125 mg/m2 over 30–40 minutes.354 Base further dose reductions in subsequent courses on individual tolerance.354

Not recommended if AST >10 times ULN, bilirubin >5 times ULN, or AST <10 times ULN and bilirubin 1.26–5 times ULN.354

Renal Impairment

Conventional paclitaxel: Reduction of dosage does not appear to be necessary.20 23 124

Cautions for Paclitaxel

Contraindications

  • Conventional Paclitaxel
  • Known hypersensitivity to paclitaxel, polyoxyl 35 castor oil (Cremophor EL, polyethoxylated castor oil), or any other ingredient in the formulation.1

  • Baseline ANC <1500/mm3 in patients with solid tumors.1

  • Baseline ANC <1000/mm3 in patients with AIDS-related Kaposi’s sarcoma.1

  • Albumin-bound Paclitaxel
  • Baseline ANC <1500/mm3.354

  • Severe hypersensitivity reaction during a previous course.354

Warnings/Precautions

Warnings

Adequate Patient Evaluation and Monitoring

Administer only under the supervision of qualified clinicians experienced in the use of cytotoxic therapy.1 354

Patients must have recovered from acute toxicities (e.g., ANC >1500/mm3 [>1000/mm3 for patients with Kaposi’s sarcoma], platelets >100,000/mm3) of previous cytotoxic therapy before each cycle.1 354

Prior to and during therapy with conventional paclitaxel, assess blood cell counts, serum bilirubin, and AST and/or ALT.1

During therapy with albumin-bound paclitaxel, assess blood cell counts frequently, including before each dose.354

Hematologic Effects

Dose-dependent and dose-limiting bone marrow suppression (mainly neutropenia).1 22 25 26 28 29 35 184 354 Thrombocytopenia occurs less commonly than neutropenia.1 25 28 29 35 354

Conventional paclitaxel: Neutrophil nadir at day 10–12, return to baseline by day 15–21.1 3 25 Platelet nadir at day 8–9.1

Cardiovascular Effects

Severe conduction abnormalities documented with conventional paclitaxel; 1 25 26 28 31 pacemaker placement needed in some patients.1 Institute appropriate therapy if clinically important conduction abnormalities occur; perform continuous cardiac monitoring during subsequent cycles.1

Hypotension, 1 26 bradycardia, 1 25 26 28 31 and hypertension1 reported during infusion of conventional paclitaxel; interruption of therapy not needed for mild symptoms.1 Interruption or discontinuance may be needed because of initial or recurrent hypertension.1

Monitor vital signs frequently during conventional paclitaxel administration, especially during the first hour of the infusion.1 Continuous cardiac monitoring not required except in patients with serious conduction abnormalities.1

Hypotension or bradycardia reported during infusion of albumin-bound paclitaxel: specific therapy or interruption of paclitaxel not needed.354 ECG abnormalities reported.354

Fetal/Neonatal Morbidity and Mortality

Embryotoxic and fetotoxic.1 354 (See Pregnancy under Cautions.)

Therapy with albumin-bound paclitaxel not advised in men wishing to father a child.354

Sensitivity Reactions

Hypersensitivity Reactions

Anaphylaxis and severe reactions, characterized by dyspnea and hypotension requiring treatment, angioedema, and generalized urticaria, reported during infusion of conventional paclitaxel.1 Fatal reactions reported in patients who received premedication.1

Anaphylaxis and severe reactions, including fatal cases, also reported during infusion of albumin-bound paclitaxel.354

Premedicate patients with corticosteroids, diphenhydramine, and histamine H2-receptor antagonists to reduce the severity of hypersensitivity reactions during infusion of conventional paclitaxel.1 (See General under Dosage and Administration.)

Interruption of therapy with conventional paclitaxel generally is not needed for mild reactions (e.g., flushing, localized skin reactions, hypotension, tachycardia).1 Discontinue immediately and treat if severe reaction occurs (hypotension requiring treatment, dyspnea requiring bronchodilators, angioedema, generalized urticaria).1

Do not administer conventional or albumin-bound paclitaxel to any patient who experienced a severe hypersensitivity reaction during a previous course.1 354 Not known whether patients who exhibit hypersensitivity to conventional paclitaxel can subsequently tolerate albumin-bound paclitaxel.354

Sulfite Sensitivity

Some formulations of conventional paclitaxel contain sulfites, which may cause allergic-type reactions (including anaphylaxis and life-threatening or less severe asthmatic episodes) in certain susceptible individuals.282 283 284 285 286 287 288 289

Major Toxicities

Nervous System Effects

Neuropathy (sensory, peripheral) occurs frequently with conventional or albumin-bound paclitaxel; severe symptoms are unusual.1 354 Neuropathy is dose and schedule dependent.354 Reduce dose for severe symptoms.1 354

Infectious Complications

Infectious episodes (e.g., sepsis, pneumonia, peritonitis, urinary and respiratory tract infections) reported with conventional paclitaxel; fatal infections reported rarely.1

Opportunistic infection reported frequently in patients with AIDS-related Kaposi's sarcoma receiving conventional paclitaxel.1 Febrile neutropenia reported more frequently with conventional paclitaxel 135 mg/m2 compared with 100 mg/m2.1

Infectious episodes (e.g., oral candidiasis, respiratory and urinary tract infections, pneumonia) reported with albumin-bound paclitaxel.354

Sepsis (irrespective of ANC) reported in patients with pancreatic cancer receiving albumin-bound paclitaxel and gemcitabine; risk factors for severe or fatal sepsis include biliary obstruction or presence of biliary stent.354 Initiate broad-spectrum anti-infectives if fever develops (regardless of ANC).354

Injection Site Reaction

Injection site reactions to conventional paclitaxel, including reactions secondary to extravasation, are mild and characterized by erythema, tenderness, skin discoloration, or swelling at the injection site.1 Reactions more frequent with the 24-hour infusion than the 3-hour infusion.1 Recurrence of skin reactions at a previous site of extravasation (i.e., “recall” reactions) following administration at a different injection site reported rarely.1 159 160

Severe events (phlebitis, cellulitis, induration, skin exfoliation, necrosis, fibrosis) reported rarely with conventional paclitaxel.1

Injection site reaction to conventional paclitaxel usually occurs during prolonged infusion; delayed onset of reaction, 3–13 days after infusion, also reported.1 157 158

Specific treatment for extravasation reactions to conventional paclitaxel unknown.1 Monitor the infusion site for possible infiltration during administration.1

Mild injection site reactions to albumin-bound paclitaxel reported infrequently.354 Monitor the infusion site for possible infiltration during administration.354

Respiratory Effects

Pneumonitis, sometimes fatal, reported infrequently with albumin-bound paclitaxel and gemcitabine.354 Monitor for pneumonitis.354 If signs and symptoms develop, interrupt therapy during evaluation; permanently discontinue therapy in patients diagnosed with pneumonitis.354

Interstitial pneumonia, lung fibrosis, radiation pneumonitis, pneumothorax, and pulmonary embolism also reported with conventional or albumin-bound paclitaxel.1 354

General Precautions

Prescribing and Dispensing Precautions

Ensure accuracy of prescription; similarity of spelling of Taxol (paclitaxel) and Taxotere (docetaxel)290 may result in errors.290

Risk of Transmissible Agents in Plasma-derived Preparations

Albumin-bound paclitaxel: Potential vehicle for transmission of viruses or other infectious agents.354 Despite screening for certain viruses, remote risk for transmission of viral infections.354 Theoretical risk for transmission of Creutzfeldt-Jacob disease.354

Specific Populations

Pregnancy

Category D.1 354

Lactation

Distributed into milk in rats; not known whether distributed into human milk.1 354 Discontinue nursing or the drug because of the potential risk to nursing infant.1 354

Pediatric Use

Safety and efficacy not established.1 354

CNS toxicity, rarely fatal, reported in pediatric patients receiving high doses of conventional paclitaxel (350–420 mg/m2) by 3-hour IV infusion.1 Paclitaxel injection contains dehydrated alcohol; toxicity may have resulted from administration of large amounts of alcohol over a short period of time.1 The use of concomitant antihistamine may intensify the toxic effect of the alcohol.1 The possibility of a direct toxic effect of paclitaxel itself cannot be ruled out.1

Geriatric Use

Conventional paclitaxel: No substantial differences in efficacy relative to younger adults.1 Severe myelosuppression and severe neuropathy reported more frequently in geriatric individuals than in younger adults.1 Increased incidence of cardiovascular events noted in geriatric patients receiving conventional paclitaxel for NSCLC.1

Albumin-bound paclitaxel for metastatic breast cancer: No difference in toxicity relative to younger adults observed in clinical studies.354

Albumin-bound paclitaxel and carboplatin for NSCLC: No overall differences in efficacy relative to younger adults, but toxicity (myelosuppression, peripheral neuropathy, arthralgia) more common in patients ≥65 years of age.354

Albumin-bound paclitaxel and gemcitabine for pancreatic cancer: No overall differences in efficacy relative to younger adults, but toxicity (diarrhea, decreased appetite, dehydration, epistaxis) more common in patients ≥65 years of age.354

Hepatic Impairment

Conventional paclitaxel: Myelotoxicity may be exacerbated in patients with total bilirubin >2 times ULN.1 Use with extreme caution in these patients; dosage adjustment recommended.1 (See Hepatic Impairment under Dosage and Administration.)

Albumin-bound paclitaxel: Toxicity may be exacerbated.354 Use with caution; adjust dosage in patients with moderate or severe impairment.354 Patients with baseline serum bilirubin exceeding the ULN were excluded from clinical trials for NSCLC and pancreatic cancer.354 (See Hepatic Impairment under Dosage and Administration.)

Renal Impairment

Albumin-bound paclitaxel: Not systematically evaluated in patients with renal impairment.354

Common Adverse Effects

Conventional paclitaxel: Alopecia, myelosuppression (neutropenia, leukopenia, anemia, thrombocytopenia), neuropathy (peripheral, sensory), myalgia/arthralgia, nausea and vomiting, diarrhea, mucositis, infection, hypersensitivity reaction, abnormal ECG, elevated alkaline phosphatase concentrations, elevated Scr.1 362

Albumin-bound paclitaxel: Alopecia, myelosuppression (neutropenia, thrombocytopenia, anemia), neuropathy (peripheral, sensory), myalgia/arthralgia, nausea, diarrhea, mucositis, fatigue/asthenia, infection, peripheral edema, abnormal ECG, elevated AST and alkaline phosphatase concentrations, elevated Scr, pyrexia, decreased appetite, rash, dehydration.354

Interactions for Paclitaxel

Metabolized by CYP2C8 and CYP3A4.1 354

Drugs Affecting or Metabolized by Hepatic Microsomal Enzymes

Pharmacokinetic interactions possible with drugs that are inhibitors, inducers, or substrates of CYP2C8 or CYP3A4 with possible alteration in metabolism of paclitaxel and/or other drug.1 354 Use concomitantly with caution.354 362

Specific Drugs

Drug

Interaction

Comments

Anticonvulsants (phenobarbital, phenytoin)

Decreased paclitaxel concentrations186 188

Carboplatin

Administration of conventional paclitaxel followed by carboplatin associated with less severe thrombocytopenia compared with carboplatin alone;186 188 204 no pharmacokinetic interaction188 204

Administration of albumin-bound paclitaxel followed by carboplatin associated with no clinically important changes in paclitaxel exposure; carboplatin AUC 23% higher than targeted value, but half-life and clearance consistent with carboplatin alone354

Cisplatin

Sequence-dependent interaction; increased severity of myelosuppression when conventional paclitaxel administered following cisplatin compared with the alternative sequence1 186 188

Paclitaxel clearance reduced by 25–33% when conventional paclitaxel administered following cisplatin1 186 188

CNS depressants

Potentiation of CNS depression due to alcohol in the conventional paclitaxel formulation1 141

Use concomitantly with caution1 141

Cyclophosphamide

Sequence-dependent interaction; increased severity of neutropenia and thrombocytopenia when conventional paclitaxel (24-hour infusion) administered before cyclophosphamide186 188

Cyclosporine

Paclitaxel metabolism inhibited in vitro at concentrations greater than usual therapeutic concentrations1 354

Dexamethasone

Paclitaxel metabolism inhibited in vitro at concentrations greater than usual therapeutic concentrations1 354

Did not displace paclitaxel from plasma proteins in vitro354 362

Diazepam

Paclitaxel metabolism inhibited in vitro at concentrations greater than usual therapeutic concentrations1 354

Diphenhydramine

Did not displace paclitaxel from plasma proteins in vitro354 362

Doxorubicin

Conventional paclitaxel: Increased plasma concentrations of doxorubicin and its active metabolite1 167 184 186 188 203

In vitro synergistic cytotoxic effects188 203

17α-Ethinyl estradiol

Paclitaxel metabolism inhibited in vitro1 354

Etoposide

Paclitaxel metabolism inhibited in vitro at concentrations greater than usual therapeutic concentrations1 354

Histamine H2-receptor antagonists

Cimetidine, famotidine: Pharmacokinetic interaction unlikely45 186 188 243

Cimetidine, ranitidine: Did not displace paclitaxel from plasma proteins in vitro354 362

HIV protease inhibitors

Possible interaction1 354

Ketoconazole

Paclitaxel metabolism inhibited in vitro at concentrations greater than usual therapeutic concentrations1 354

Quinidine

Paclitaxel metabolism inhibited in vitro at concentrations greater than usual therapeutic concentrations1 354

Teniposide

Paclitaxel metabolism inhibited in vitro at concentrations greater than usual therapeutic concentrations1 354

Testosterone

Paclitaxel metabolism inhibited in vitro1 354

Verapamil

Paclitaxel metabolism inhibited in vitro at concentrations greater than usual therapeutic concentrations1 354

Vincristine

Paclitaxel metabolism inhibited in vitro at concentrations greater than usual therapeutic concentrations1 354

Paclitaxel Pharmacokinetics

Absorption

Conventional paclitaxel: Exhibits nonlinear pharmacokinetic behavior when administered over short periods (i.e., 3 hours).35 183 186 196

Albumin-bound paclitaxel: Increase in AUC proportional to increase in dose for doses of 80–375 mg/m2.354 Duration of infusion does not affect pharmacokinetics.354

Special Populations

Conventional paclitaxel: Plasma paclitaxel exposure increased with abnormal serum bilirubin concentrations ≤2 times ULN.1

Albumin-bound paclitaxel: Plasma paclitaxel exposure following 260- or 200-mg/m2 dose in patients with mild or moderate hepatic impairment, respectively, was similar to exposure observed in patients with normal hepatic function.354 364

Distribution

Extent

Widely distributed.1 45 183 184

Conventional paclitaxel is detected in ascitic fluid;20 45 does not penetrate the CNS.20 45 183 184 186 199

Not known whether paclitaxel is distributed into human milk.1 354

Following administration of albumin-bound paclitaxel, concentration of drug in tumor cells is increased compared with concentration achieved following an equivalent dose of conventional paclitaxel.357

Plasma Protein Binding

88–98%.1 20 354

Elimination

Metabolism

Metabolized by CYP2C8 and, to a lesser extent, by CYP3A4.1 202 354

Elimination Route

Excreted principally in feces as metabolites and unchanged drug.184 196 197 205 246

Minimal urinary excretion.183 184 196 197 198 205

Half-life

Conventional paclitaxel: Average elimination half-life: 5.8 hours for 6- to 24-hour infusions,186 2.33 hours for 3-hour infusions.246

Albumin-bound paclitaxel: 27 hours.354

Stability

Storage

Parenteral

For Injection Concentrate (Conventional Paclitaxel)

20–25°C in the original package to protect from light.1

No adverse effect on drug from freezing or refrigeration.1 Drug or vehicle that precipitates during refrigeration or freezing will redissolve at room temperature without potency loss.1 23

Solutions for infusion are stable at ambient temperature (approximately 25°C) and lighting conditions for up to 27 hours.1

Suspension for Injection (Albumin-bound Paclitaxel)

20–25°C in the original package to protect from bright light.354

Use reconstituted suspension immediately; alternatively, store vial in the original package for up to 8 hours at 2–8°C.354 No adverse effect on drug from freezing or refrigeration.354

Discard reconstituted suspension if precipitation occurs.354

Reconstituted suspension for infusion is stable in the IV infusion bag at ambient temperature (approximately 25°C) and lighting conditions for up to 4 hours.354

Compatibility

For information on systemic interactions resulting from concomitant use, see Interactions.

Parenteral

Solution Compatibility (Conventional Paclitaxel)HID

Compatible

Sodium chloride 0.9%

Variable

Dextrose 5% in water; white precipitate noted occasionally distal to pump chamber

Drug Compatibility (Conventional Paclitaxel)
Admixture CompatibilityHID

Compatible

Carboplatin

Doxorubicin HCl

Variable

Cisplatin

Y-site CompatibilityHID

Compatible

Acyclovir sodium

Amikacin sulfate

Aminophylline

Ampicillin sodium–sulbactam sodium

Anidulafungin

Bleomycin sulfate

Butorphanol tartrate

Calcium chloride

Carboplatin

Cefotetan disodium

Ceftazidime

Ceftriaxone sodium

Cisplatin

Cladribine

Cyclophosphamide

Cytarabine

Dacarbazine

Dexamethasone sodium phosphate

Diphenhydramine HCl

Doripenem

Doxorubicin HCl

Droperidol

Etoposide

Etoposide phosphate

Famotidine

Floxuridine

Fluconazole

Fluorouracil

Furosemide

Ganciclovir sodium

Gemcitabine HCl

Gentamicin sulfate

Granisetron HCl

Haloperidol lactate

Heparin sodium

Hydrocortisone sodium succinate

Hydromorphone HCl

Ifosfamide

Linezolid

Lorazepam

Magnesium sulfate

Mannitol

Meperidine HCl

Mesna

Methotrexate sodium

Metoclopramide HCl

Morphine sulfate

Nalbuphine HCl

Ondansetron HCl

Ondansetron HCl with ranitidine HCl

Oxaliplatin

Palonosetron HCl

Pemetrexed disodium

Pentostatin

Potassium chloride

Prochlorperazine edisylate

Propofol

Ranitidine HCl

Sodium bicarbonate

Thiotepa

Topotecan HCl

Vancomycin HCl

Vinblastine sulfate

Vincristine sulfate

Zidovudine

Incompatible

Amphotericin B

Amphotericin B cholesteryl sulfate complex

Chlorpromazine HCl

Doxorubicin HCl liposome injection

Hydroxyzine HCl

Methylprednisolone sodium succinate

Mitoxantrone HCl

Actions

  • A natural or semisynthetic diterpene extracted from the bark of the Western (Pacific) yew (Taxus brevifolia) or produced from the needles and twigs of a more prevalent yew (Taxus baccata).2 3 4 6 7 20 22 35 71 183 Structurally and pharmacologically similar to docetaxel.206 246

  • Disrupts the microtubular network in cells that is essential for mitotic and interphase cellular function.1 354

Advice to Patients

  • Importance of recognizing and reporting adverse effects including myelosuppressive effects and infectious complications.1 354

  • Importance of reporting adverse effects including persistent vomiting, diarrhea, or signs of dehydration.354

  • Advise patient about sensory neuropathy.354 Importance of reporting numbness, tingling, pain, or weakness involving the extremities.354

  • Importance of reading the patient information leaflet.1

  • Advise patient about probable alopecia, fatigue/asthenia, and myalgia/arthralgia.1 354

  • Advise patient about risk of severe or fatal hypersensitivity reaction.354

  • Advise patient about risk of pneumonitis.354 Importance of reporting sudden onset of dry persistent cough or shortness of breath.354

  • Potential for alcohol in conventional paclitaxel to impair mental alertness or physical coordination; avoid driving or operating machinery until effects on individual known.1 141

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed; necessity for clinicians to advise women to avoid pregnancy during therapy.1 354 Importance of advising men to avoid fathering a child during therapy.354 (See Fetal/Neonatal Morbidity and Mortality under Cautions.)

  • Importance of patients informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.1 354

  • Importance of informing patients of other important precautionary information.1 354 (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Paclitaxel

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Parenteral

For injection, concentrate, for IV infusion

6 mg/mL*

Onxol

Teva

Paclitaxel Injection

Paclitaxel (albumin-bound)

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Parenteral

For injectable suspension, for IV infusion

100 mg (of paclitaxel)

Abraxane

Celgene

AHFS DI Essentials. © Copyright, 2004-2014, Selected Revisions October 3, 2014. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Bristol-Myers Squibb. Taxol (paclitaxel) injection prescribing information. Princeton, NJ; 2003 Mar.

2. Horwitz SB. Mechanism of action of taxol. Trends Pharmacol Sci. 1992; 13:134- 6. [PubMed 1350385]

3. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst. 1990; 82:1247-59. [PubMed 1973737]

4. Nightingale SL. Treatment IND/group C distribution for advanced metastatic ovarian cancer. JAMA. 1992; 268:1390. [PubMed 1380995]

5. Folkemer M, Bennett S. Nation calls for increased yew tree collection. J Natl Cancer Inst. 1992; 84:479-80. [PubMed 1347571]

6. Kingston DGI. The chemistry of taxol. Pharmacol Ther. 1991; 52:1-34. [PubMed 1687170]

7. National Cancer Institute Cancer Therapy Evaluation Program. Treatment referral center protocol: Taxol (NSC 125973) in refractory ovarian cancer. NCI protocol TRC-9103. Bethesda, MD: National Cancer Institute; 1992 Jun 1.

8. Stone R. Surprise! A fungus factory for taxol? Science. 1993; 260:154-5.

9. Stierle A, Strobel G, Stierle D. Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of Pacific yew. Science. 1993; 260:214-6. [PubMed 8097061]

10. US Food and Drug Administration. Taxol approved for ovarian cancer. Rockville, MD: 1992 Dec 29. Press release.

11. Waugh WN, Trissel LA, Stella VJ. Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers. Am J Hosp Pharm. 1991; 48:1520-4. [IDIS 282611] [PubMed 1679294]

12. Pearson SD, Trissel LA. Evaluation of diethylhexyl phthalate leaching from polyvinyl chloride containers by selected drugs and formulation components. Program and abstracts of the 27th Annual ASHP Midyear Clinical Meeting. Orlando, FL: 1992 Dec 6-10. Abstract P-356E.

13. Rowinsky EK, Donehower RC. Taxol: twenty years later, the story unfolds. J Natl Cancer Inst. 1991; 83:1778-81. [PubMed 1683907]

14. Hand R, Fremgen A, Chmiel JS et al. Staging procedures, clinical management, and survival outcome for ovarian carcinoma. JAMA. 1993; 269:1119-22. [PubMed 8433466]

15. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. BMJ. 1991; 303:884-93. [IDIS 286684] [PubMed 1834291]

16. Cruickshank DJ. Chemotherapy in advanced ovarian cancer. BMJ. 1991; 303:1269. [PubMed 1747658]

17. Izard M. Chemotherapy in advanced ovarian cancer. BMJ. 1992; 304:119. [IDIS 290619] [PubMed 1531310]

18. Stewart LA, Guthrie D, Parmar MKB et al. Chemotherapy in advanced ovarian cancer. BMJ. 1992; 304:119.

19. Richardson GS. Ovarian cancer. JAMA. 1993; 269:1163. [PubMed 8433473]

20. Gregory RE, DeLisa AF. Paclitaxel: a new antineoplastic agent for refractory ovarian cancer. Clin Pharm. 1993; 12:401-15. [IDIS 314324] [PubMed 7691462]

21. Weiss RB, Donehower RC, Wiernik PH et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990; 8:1263-8. [PubMed 1972736]

22. Anon. Paclitaxel (Taxol) for ovarian cancer. Med Lett Drugs Ther. 1993; 35:39- 40. [PubMed 8097551]

23. Bristol-Myers Squibb, Princeton, NJ: Personal communication.

24. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994; 12:2654-66. [IDIS 339632] [PubMed 7989941]

25. Rowinsky EK, Gilbert MR, McGuire WP et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol. 1991; 9:1692-703. [PubMed 1678780]

26. Sarosy G, Kohn E, Stone DA et al. Phase I study of taxol and granulocyte colony- stimulating factor in patients with refractory ovarian cancer. J Clin Oncol. 1992; 10:1165- 70. [PubMed 1376773]

27. Anon. Taxol/G-CSF combination reduced ovarian tumors by 50% in half of patients. F-D-C Reports. 1992 Apr 20.

28. McGuire WP, Rowinsky EK, Rosenshein NB et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989; 111:273-9. [IDIS 257909] [PubMed 2569287]

29. Einzig AI, Wiernik PH, Sasloff J et al. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol. 1992; 10:1748-53. [PubMed 1357110]

30. Lipton RB, Apfel SC, Dutcher JP et al. Taxol produces a predominantly sensory neuropathy. Neurology. 1989; 39:368-73. [IDIS 252921] [PubMed 2564647]

31. Rowinsky EK, McGuire WP, Guarnieri T et al. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991; 9:1704-12. [PubMed 1678781]

32. Raghavan VT, Bloomer WD, Merkel DE. Taxol and radiation recall dermatitis. Lancet. 1993; 341:1354. [IDIS 314796] [PubMed 8098490]

33. Bicher A, Sarosy G, Kohn E et al. Age does not influence taxol dose intensity in recurrent carcinoma of the ovary. Cancer. 1993; 71(2 Suppl):594-600. [IDIS 308162] [PubMed 7678382]

34. Food and Drug Administration. Prescription drug advertising; content and format for labeling of human prescription drugs. Fed Regist. 1979; 44:37434-67.

35. Mead Johnson Oncology Products, Bristol-Myers Squibb. Taxol (paclitaxel) for injection concentrate prescribing information. Princeton, NJ; 1992 Dec 29.

36. Holmes FA, Walters RS, Theriault RL et al. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991; 83:1797-1805. [PubMed 1683908]

37. Seidman AD, Norton L, Reichman BS et al. Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer. Semin Oncol. 1993; 20(Suppl 3):40-5. [PubMed 7688145]

38. Reichman BS, Seidman AD, Crown JPA et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol. 1993; 11:1943-51. [PubMed 7691998]

39. Reichman BS, Seidman AD, Crown JPA et al. Taxol and recombinant human granulocyte colony-stimulating factor, an active regimen as initial therapy for metastatic breast cancer: a preliminary report. Ann N Y Acad Sci. 1993; 698:398-402. [PubMed 7506506]

40. Holmes FA, Frye D, Valero V et al. Phase I study of Taxol (T) and doxorubicin (D) with G-CSF in patients (PTS) without prior chemotherapy (CT) for metastatic breast cancer (MBC). Proc Annu Meet Am Soc Clin Oncol. 1992; 11:A66.

41. Holmes FA, Valero V, Theriault RL et al. Phase II trial of Taxol (T) in metastatic breast cancer (MBC) refractory to multiple prior treatments. Proc Annu Meet Am Soc Clin Oncol. 1993; 12:A178.

42. Nabholtz JM, Gelmon K, Bontenbal M et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol. 1996; 14:1858-67. [IDIS 369586] [PubMed 8656254]

43. Long HJ. Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug. Mayo Clin Proc. 1994; 69:341-5. [IDIS 327290] [PubMed 7909575]

44. Arbuck SG. Paclitaxel: what schedule? what dose? J Clin Oncol. 1994; 12:233-6. Editorial. (IDIS 326004)

45. Kohler DR, Goldspiel BR. Paclitaxel (Taxol). Pharmacotherapy. 1994; 14:3-34. [IDIS 325155] [PubMed 7909150]

46. Wilson WH, Berg SL, Bryant G et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol. 1994; 12:1621-9. [IDIS 334293] [PubMed 7913721]

47. Fisherman JS, McCabe M, Noone M et al. Phase I study of Taxol, doxorubicin, plus granulocyte-colony stimulating factor in patients with metastatic breast cancer. Monogr Natl Cancer Inst. 1993; 15:189-94. [PubMed 7517154]

48. Bristol-Myers Squibb. Taxol (paclitaxel) for injection concentrate in breast cancer (product monograph). Princeton, NJ; 1993 May. Publication K4-W011.

49. Seidman A, Crown J, Reichman B et al. Lack of clinical cross-resistance of Taxol (T) with anthracycline (A) in the treatment of metastatic breast cancer (MBC). Proc Annu Meet Am Soc Clin Oncol. 1993; 12:A53.

50. Schiller JH, Storer B, Tutsch K et al. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol. 1994; 12:241-248. [IDIS 326005] [PubMed 7509380]

51. Canetta R, Gelmon K, Hortobagyi GN et al. The current role of Taxol (paclitaxel) for injection concentrate in the treatment of metastatic breast cancer (product information). Princeton, NJ: Bristol-Myers Squibb Company; 1994 Mar.

52. Brown T, Havlin K, Weiss G et al. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol. 1991; 9:1261-7. [PubMed 1675263]

53. Murphy WK, Fossella FV, Winn RJ et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst. 1993; 85:384-8. [PubMed 8094466]

54. Chang AY, Kim K, Glick J et al. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst. 1993; 85:388-94. [PubMed 8094467]

55. Eisenhauer EA. Taxol in advanced non-small-cell lung cancer: plus ca change? J Natl Cancer Inst. 1993; 85:346-7. Editorial.

56. Green MR. New directions for chemotherapy in non-small-cell lung cancer. Chest. 1993; 103(Suppl):S370-2.

57. Johnson DH, Paul DM, Hande KR et al. Paclitaxel plus carboplatin in advanced non- small-cell lung cancer: a phase II trial. J Clin Oncol. 1996; 14:2054-60. [IDIS 370183] [PubMed 8683236]

58. Israel VK, Zaretsky S, Natale RB. Phase I/II trial of combination carboplatin and taxol in advanced non-small cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol. 1994; 13:A1175.

59. Klastersky J, Sculier JP. Paclitaxel (P) plus cisplatin (C) in non-small cell lung cancer: a dose finding study. Proc Annu Meet Am Soc Clin Oncol. 1994; 13:A1169.

60. Hainsworth JD, Miller P, Menchise A et al. Treatment of locally advanced non-small cell lung cancer (NSCLC) with taxol (1-hr infusion), cisplatin, etoposide, and radiation therapy (RT): a phase II trial. Proc Annu Meet Am Soc Clin Oncol. 1994; 13:A1172.

61. Choy H, Safran H, Akerley W et al. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res. 1998; 4:1931-6. [IDIS 409473] [PubMed 9717821]

62. Forastiere AA, Rowinsky E, Chaudry V et al. Phase I trial of taxol (T) and cisplatin (C) + G-CSF in solid tumors. Proc Annu Meet Am Soc Clin Oncol. 1992; 11:A289.

63. Murphy WK, Winn RJ, Huber M et al. Phase II study of taxol (T) in patients (pts) with non-small cell lung cancer (NSCLC) who have failed platinum (P) containing chemotherapy (Ctx). Proc Annu Meet Am Soc Clin Oncol. 1994; 13:A1224.

64. Reviewers’ comments (personal observations).

65. Hudis C, Seidman a, Baselga J et al. Sequential high dose adjuvant doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) with G-CSF (G) is feasible for women patients (pts) with resected breast cancer (BC) and greater than or equal to 4(+) lymph nodes (LN). Proc Annu Meet Am Soc Clin Oncol. 1994; 13:A62.

66. Demetri GD, Berry D, Younger J et al. Dose-intensified cyclophosphamide/doxorubicin (CD) followed by taxol (T) as adjuvant systemic chemotherapy for node-positive breast cancer (CALGB 9141): randomized comparison of two dose levels of G-CSF. Proc Annu Meet Am Soc Clin Oncol. 1994; 13:A63.

67. Seidman AD, Barrett S, Hudis C et al. Three hour taxol infusion as initial (I) and as salvage (S) chemotherapy of metastatic breast cancer (MBC). Proc Annu Meet Am Soc Clin Oncol. 1994; 13:A65.

68. Seidman AD, Hochhauser D, Gollub M et al. Ninety-six–hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol. 1996; 14:1877-84. [IDIS 369587] [PubMed 8656256]

69. Demetri GD. The use of hematopoietic growth factors to support cytotoxic chemotherapy for patients with breast cancer. Hematol Oncol Clin North Am. 1994; 8:233-49. [PubMed 8150782]

70. Miller LL. Current status of G-CSF in support of chemotherapy and radiotherapy. Oncology (Huntington). 1993; 7:67-78,81-4,87-8.

71. Bristol-Myers Squibb. FDA clears anticancer drug Taxol (paclitaxel) produced semisynthetically from renewable sources. Princeton, NJ; 1994 Dec 12. Press release.

72. Hidalgo M, Benito J, Colomer R et al. Recall reaction of a severe local peripheral neuropathy after paclitaxel extravasation. J Natl Cancer Inst. 1996; 88:1320. [PubMed 8797774]

73. Perry JR, Warner E. Transient encephalopathy after paclitaxel (Taxol) infusion. Neurology. 1996; 46:1596-9. [IDIS 368524] [PubMed 8649555]

74. Solimando DA, Phillips ET, Weiss RB et al. Hypertensive reactions associated with paclitaxel. Cancer Invest. 1996; 14:340-2. [PubMed 8689429]

75. Gianni L, Munzone E, Capri G et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol. 1995; 13:2688- 99. [IDIS 355435] [PubMed 7595726]

76. Rose PG, Piver MS. Intestinal perforation secondary to paclitaxel. Gynecol Oncol. 1995; 57:270-2. [PubMed 7729749]

77. Seewaldt V, Cain JM, Greer BE et al. Bowel complications with taxol therapy. J Clin Oncol. 1993; 11:1198. [PubMed 8099122]

78. Hoff PM, Valero V, Holmes FA et al. Paclitaxel-induced pancreatitis: a case report. J Natl Cancer Inst. 1997; 89:91-3. [IDIS 378859] [PubMed 8978416]

79. Pestalozzi BC, Sotos GA, Choyke PL et al. Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer. Cancer. 1993; 71:1797- 1800. [IDIS 310886] [PubMed 8095437]

80. Smith RE, Thornton DE, Allen J. A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol. 1995; 22(3 Suppl 6):41-6. [PubMed 7597432]

81. Catimel G. Head and neck cancer: guidelines for chemotherapy. Drugs. 1996; 51:73-88. [PubMed 8741233]

82. Lip and oral cavity cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2005 Jun 17.

83. Oropharyngeal cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2006 Mar 10.

84. Hypopharyngeal cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2005 Jul 11.

85. Laryngeal cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2006 Mar 6.

86. Chougoule P, Wanebo H, Akerley W et al. Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: a phase II study—preliminary results. Semin Oncol. 1997; 24(6 Suppl 19):57-61. [PubMed 9045305]

87. Licitra L, Capri G, Fulfaro F et al. Biweekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma: a phase II trial. Ann Oncol. 1997; 8:1157-8. [PubMed 9426337]

88. Hitt R, Hornedo J, Colomer R et al. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results. Semin Oncol. 1995; 22(6 Suppl 15):50-4. [PubMed 8643971]

89. Vokes EE, Weichselbaum RR, Lippman SM et al. Head and neck cancer. N Engl J Med. 1993; 328: 184-94.

90. Forastiere AA, Flood WA, Koch W et al. Phase I study of paclitaxel administered over 96 hours and cisplatin in patients with locally advanced squamous cell cancer of the head and neck. Proc Am Soc Clin Oncol. 1996; 15:314.

91. Forastiere AA. Head and neck malignancies. Basic Clin Oncol. 1995; 8:287-94.

92. Flood WA, Lee DJ, Trotti A et al. A phase I study of weekly paclitaxel and cisplatin concurrent with postoperative radiation therapy for treatment of high-risk patients with squamous cell cancer of the head and neck. Proc Am Soc Clin Oncol. 1996; 15:314.

93. Forastiere AA, Urba SG. Single-agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer. Semin Oncol. 1995; 22(3 Suppl 6):24-7. [PubMed 7597431]

94. Vokes EE, Stupp R, Haraf D et al. Hydroxyurea with continuous infusion paclitaxel, 5- fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer. Semin Oncol. 1995; 22(3 Suppl 6):47-52. [PubMed 7597433]

95. Rosenthal DI, Carbone DP. Taxol plus radiation for head and neck cancer. J Infus Chemother. 1995; 5:46-54. [PubMed 8521234]

96. Forastiere AA. Paclitaxel (Taxol) for the treatment of head and neck cancer. Semin Oncol. 1994; 21(5 Suppl 8):49-52. [PubMed 7939763]

97. Ettinger DS, Finkelstein DM, Sarma RP et al. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1995; 13:1430-5. [IDIS 348859] [PubMed 7751889]

98. Kirschling RJ, Grill JP, Marks RS et al. Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group. Am J Clin Oncol. 1999; 22:517-22. [IDIS 433193] [PubMed 10521070]

99. Birch R, Weaver CH, Hainsworth JD et al. A randomized study of etoposide and carboplatin with or without paclitaxel in the treatment of small cell lung cancer. Semin Oncol. 1997; 24(Suppl 12):S135-7.

100. Levitan N, McKenney J, Tahsildar H et al. Results of a phase I dose escalation trial of paclitaxel, etoposide, and cisplatin followed by filgrastim in the treatment of patients with extensive stage small cell lung cancer. Proc Am Soc Clin Oncol. 1995; 14:379.

101. Bunn PA Jr, Kelly K. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer. Semin Oncol. 1997; 24(Suppl 12):144-8.

102. Gatzemeier U, Jagos U, Kaukel E et al. Paclitaxel, carboplatin, and oral etoposide: a phase II trial in limited-stage small cell lung cancer. Semin Oncol. 1997; 24(Suppl 12):149- 52.

103. Hainsworth JD, Stroup SL, Greco FA. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma. Cancer. 1996; 77:2458-63. [IDIS 368302] [PubMed 8640693]

104. Roth BJ, Eastern Cooperative Oncology Group, principal investigator. Phase III randomized study of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) versus carboplatin and paclitaxel for the treatment of advanced carcinoma of the urothelium (summary last modified 01/1999). Protocol ID: E-4897. From CancerNet: PDQ Clinical Trials (database). Bethesda, MD: National Cancer Institute.

105. Ihde DC. Chemotherapy of lung cancer. N Engl J Med. 1992; 327:1434-41. [IDIS 304946] [PubMed 1328881]

106. Ettinger DS. New drugs for treating small cell lung cancer. Lung Cancer. 1995; 12(Suppl 3):S53-61. [PubMed 7551957]

107. Bunn PA Jr. Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions. Semin Oncol. 1997; 24(Suppl 12):153-62. [PubMed 9129685]

108. Small cell lung cancer. From PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2006 Mar 6.

109. Esophageal cancer. From: PDQ. Physician data query(database). Bethesda, MD: National Cancer Institute; 2006 Feb 22.

110. Kelsen DP, Ilson DH. Chemotherapy and combined-modality therapy for esophageal cancer. Chest. 1995; 107:S224-32. [IDIS 349949] [PubMed 7781398]

111. Ajani JA, Ilson DH, Daugherty K et al. Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst. 1994; 86:1086- 91. [IDIS 332458] [PubMed 7912736]

112. Javed T, Reed C, Walle T et al. A regimen of paclitaxel (P), cisplatin (CP) and 5- fluorouracil (FU) followed by G-CSF is highly active against epidermoid and adenocarcinoma of the esophagus. Proc Am Soc Clin Oncol. 1995; 14:195.

113. Ilson DH, Ajani J, Bhalla K et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol. 1998; 16:1826-34. [IDIS 406124] [PubMed 9586897]

114. Ajani JA, Ilson DH, Kelsen DP. The activity of paclitaxel in gastrointestinal tumors. Semin Oncol. 1995; 22(5 Suppl 12):46-50. [PubMed 7481861]

115. Shenkier T, Gelmon K. Paclitaxel and radiation-recall dermatitis. J Clin Oncol. 1994; 12:439. [IDIS 326023] [PubMed 7906725]

116. Miles SA, Aboulafia DM, Mitsuyasu RI. AIDS-related malignancies. In: DeVita VT Jr, Hellman S, Rosenberg SA eds. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven Publishers; 1997:2445-67.

117. Saville MW, Lietzau J, Pluda JM et al. Treatment of HIV-related Kaposi’s sarcoma with paclitaxel. Lancet. 1995; 346:26-8. [IDIS 348839] [PubMed 7603142]

118. Gill PS, Tulpule A, Reynolds T et al. Paclitaxel (Taxol) in the treatment of relapsed or refractory advanced AIDS-related Kaposi’s sarcoma. Proc Annu Meet Am Soc Clin Oncol. 1996; 15:306.

119. Mega A, Akhtar MS, Safran H et al. Low dose weekly paclitaxel for HIV associated Kaposi’s sarcoma. Proc Annu Meet Am Soc Clin Oncol. 1996; 15:307.

120. Kaposi’s sarcoma. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2006 Mar 20.

121. Anon. Bristol Taxol Kaposi’s sarcoma protease inhibitor and Doxil comparison studies planned: committee leaves Taxol KS dosing decision to FDA. F-D-C Rep. 1997 Jun 30.

122. Anon. Drugs of choice for cancer. Treat Guidel Med Lett. 2003; 1:41-52. [PubMed 15529105]

123. Krown SE, Metroka C, Wernz JC. Kaposi’s sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. J Clin Oncol. 1989; 7:1201-7. [PubMed 2671281]

124. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med. 1995; 332:1004-14. [IDIS 345131] [PubMed 7885406]

125. Seidman AD, Reichman BS, Crown JPA et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol. 1995; 13:1152-9. [IDIS 347749] [PubMed 7537798]

126. Seidman AD, Tiersten A, Hudis C et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol. 1995; 13:2575-81. [IDIS 356138] [PubMed 7595709]

127. Gianni L, Munzone E, Capri G et al. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst. 1995; 87:1169-75. [IDIS 351616] [PubMed 7674322]

128. Michael M, Bishop JF, Levi JA et al. Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy. Med J Aust. 1997; 166:520-3. [IDIS 386845] [PubMed 9196484]

129. Thigpen JT, Blessing JA, Ball H et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol. 1994; 12:1748-53. [IDIS 335222] [PubMed 7916038]

130. Kohn EC, Sarosy G, Bicher A et al. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst. 1994; 86:18-24. [IDIS 323940] [PubMed 7505830]

131. Trimble EL, Adams JD, Vena D et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol. 1993; 11:2405-10. [PubMed 7902426]

132. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996; 334:1-6. [IDIS 357593] [PubMed 7494563]

133. Neijt JP. New therapy for ovarian cancer. N Engl J Med. 1996; 334:50-1. [PubMed 7494573]

134. Ovarian epithelial cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2006 Mar 6.

135. NIH Consensus Development Panel on Ovarian Cancer. NIH consensus conference on ovarian cancer: screening, treatment, and follow-up. JAMA. 1995; 273:491-7. [IDIS 341812] [PubMed 7837369]

136. Kristensen GB, Trope C. Epithelial ovarian carcinoma. Lancet. 1997; 349:113- 7. [IDIS 379735] [PubMed 8996432]

137. Connelly E, Markman M, Kennedy A et al. Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol. 1996; 62:166-8. [PubMed 8751544]

138. Cavaletti G, Bogliun G, Crespi V et al. Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer. J Clin Oncol. 1997; 15:199-206. [IDIS 379612] [PubMed 8996143]

139. Food and Drug Administration. Orphan designations pursuant to Section 526 of the Federal Food and Drug Cosmetic Act as amended by the Orphan Drug Act (P.L. 97-414), to August 8, 1997. Rockville, MD; 1997 Aug.

140. Bower JH. Temporary worsening of parkinsonism in a patient with Parkinson’s disease after treatment with paclitaxel for a metastatic grade IV adenocarcinoma. Mov Disord. 1995; 10:681-2. [PubMed 8552128]

141. Wilson DB, Beck TM, Gundlach CA. Paclitaxel formulation as a cause of ethanol intoxication. Ann Pharmacother. 1997; 31:873-5. [IDIS 389355] [PubMed 9220050]

142. Alagaratnam TT. Sudden death 7 days after paclitaxel infusion for breast cancer. Lancet. 1993; 342:1232-3. [IDIS 322251] [PubMed 7901542]

143. Jekunen A, Heikkila P, Maiche A et al. Paclitaxel-induced myocardial damage detected by electron microscopy. Lancet. 1994; 343:727-8. [IDIS 327258] [PubMed 7907690]

144. Sevelda P, Mayerhofer K, Obermair A et al. Thrombosis with paclitaxel. Lancet. 1994; 343:727. [IDIS 327257] [PubMed 7907689]

145. Hekmat E. Fatal myocardial infarction potentially induced by paclitaxel. Ann Pharmacother. 1996; 30:1110-2. [IDIS 373322] [PubMed 8893117]

146. Faivre S, Goldwasser F, Soulie P et al. Pacitaxel (Taxol)-associated junctional tachycardia. Anti-Cancer Drugs. 1997; 8:714-6. [PubMed 9311449]

147. de Argila D, Dominguez JD, Iglesias L. Taxol-induced acral erythema. Dermatology. 1996; 192:377-8. [PubMed 8864381]

148. Weinberg JM, Egan CL, Tangoren IA et al. Generalized pustular dermatosis following paclitaxel therapy. Int J Dermatol. 1997; 36:559-60. [PubMed 9268763]

149. Young PC, Montemarano AD, Lee N et al. Hypersensitivity to paclitaxel manifested as a bullous fixed drug eruption. J Am Acad Dermatol. 1996; 34:313-4. [IDIS 363967] [PubMed 8642105]

150. Goldberg HL, Vannice SB. Pneumonitis related to treatment with paclitaxel. J Clin Oncol. 1995; 13:534-5. [IDIS 342614] [PubMed 7844618]

151. Ramanathan RK, Reddy VV, Holbert JM et al. Pulmonary infiltrates following administration of paclitaxel. Chest. 1996; 110:289-92. [IDIS 370535] [PubMed 8681647]

152. Capri G, Munzone E, Tarenzi E et al. Optic nerve disturbances: a new form of paclitaxel neurotoxicity. J Natl Cancer Inst. 1994; 86:1099-1101. [IDIS 332461] [PubMed 7912737]

153. Phillips KA, Urch M, Bishop JF. Radiation-recall dermatitis in a patient treated with paclitaxel. J Clin Oncol. 1995; 13:305. [IDIS 340541] [PubMed 7799038]

154. Bokemeyer C, Lampe C, Heneka M et al. Paclitaxel-induced radiation recall dermatitis. Ann Oncol. 1996; 7:755-6. [PubMed 8905038]

155. McCarty MJ, Peake MF, Lillis P et al. Paclitaxel-induced radiation recall dermatitis. Med Pediatr Oncol. 1996; 27:185-6. [PubMed 8699997]

156. Feenstra J, Vermeer RJ, Stricker BH. Fatal hepatic coma attributed to paclitaxel. J Natl Cancer Inst. 1997; 89:582-3. [IDIS 385513] [PubMed 9106649]

157. Bicher A, Levenback C, Burke TW et al. Infusion site soft-tissue injury after paclitaxel administration. Cancer. 1995; 76:116-20. [IDIS 349390] [PubMed 8630862]

158. Herrington JD, Figueroa JA. Severe necrosis due to paclitaxel extravasation. Pharmacotherapy. 1997; 17:163-5. [IDIS 378752] [PubMed 9017777]

159. Shapiro J, Richardson GE. Paclitaxel-induced “recall” soft tissue injury occurring at the site of previous extravasation with subsequent intravenous treatment in a different limb. J Clin Oncol. 1994; 12:2237-8. [IDIS 337249] [PubMed 7931497]

160. Meehan JL, Sporn JR. Case report of Taxol administration via central vein producing a recall reaction at a site of prior Taxol extravasation. J Natl Cancer Inst. 1994; 86:1250-1. [IDIS 334216] [PubMed 7913725]

161. Reckzeh B, Merte H, Pfluger KH et al. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. J Clin Oncol. 1996; 14:1071-6. [IDIS 366495] [PubMed 8648359]

162. Ramanathan RK, Belani CP. Transient pulmonary infiltrates: a hypersensitivity reaction to paclitaxel. Ann Intern Med. 1996; 124:278. [IDIS 359303] [PubMed 8534016]

163. Seidman AD, Barrett S, Canezo S. Photopsia during 3-hour paclitaxel administration at doses ≥ 250 mg/m2. J Clin Oncol. 1994; 12:1741-2. [IDIS 334305] [PubMed 7913722]

164. Chan AT, Leung WT, Johnson PJ. Cerebrovascular event following taxol infusion. Clin Oncol (R Coll Radiol). 1994; 6:202-3. [PubMed 7916203]

165. Freilich RJ, Seidman AD. Pruritis caused by 3-hour infusion of high-dose paclitaxel and improvement with tricyclic antidepressants. J Natl Cancer Inst. 1995; 87:933-4. [IDIS 349254] [PubMed 7666485]

166. Schweitzer VG, Juillard GJ, Bajada CL et al. Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Cancer. 1995; 76:1069-72. [IDIS 354130] [PubMed 8625210]

167. Gianni L, Vigano L, Locatelli A et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol. 1997; 15:1906-15. [IDIS 387790] [PubMed 9164201]

168. Roth BJ, Dreicer R, Einhorn LH et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 1994; 12:2264-70. [IDIS 338058] [PubMed 7525883]

169. Dreicer R, Gustin DM, See WA et al. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J Urol. 1996; 156:1606-8. [IDIS 374961] [PubMed 8863548]

170. Papamichael D, Gallagher CJ, Oliver RTD et al. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer. 1997; 75:606-7. [PubMed 9052419]

171. Tu SM, Hossan E, Amato R et al. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol. 1995; 154:1719-22. [IDIS 354688] [PubMed 7563331]

172. Murphy BA, Johnson DR, Smith J et al. Phase II trial of paclitaxel (P) and cisplatin (C) for metastatic or locally unresectable urothelial cancer. Proc Am Soc Clin Oncol. 1996; 15:245.

173. Bajorin DF, McCaffrey JA, Hilton S et al. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial. J Clin Oncol. 1998; 16:2722-7. [IDIS 410695] [PubMed 9704723]

174. Vaughn DJ, Malkowicz SB, Zoltick B et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol. 1998; 16:255-60. [IDIS 397607] [PubMed 9440750]

175. Bokemeyer C, Hartmann JT, Kuczyk MA et al. The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ- cell tumors. World J Urol. 1996; 14:354-9. [PubMed 8986035]

176. Roth BJ. The role of paclitaxel in the therapy of bladder cancer. Semin Oncol. 1995; 22(Suppl 12):33-40. [PubMed 7481859]

177. Ilson D, Arquette M, Costa F et al. Preoperative paclitaxel/cisplatin in esophageal carcinoma: a phase II multicenter trial. Proc Am Soc Clin Oncol. 1997; 16:261a.

178. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000; 92:699-708. [IDIS 448100] [PubMed 10793106]

179. Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2000; 18:106-15. [IDIS 438908] [PubMed 10623700]

180. Forastiere AA, Shank D, Neuberg D et al. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer. 1998; 82:2270-4. [IDIS 407278] [PubMed 9610709]

181. Rowinsky EK, Mackey MK, Goodman SN. Meta-analysis of paclitaxel (P) dose- reponse and dose intensity (DI) in recurrent or refractory ovarian cancer (OC). Proc Annu Meet Am Soc Clin Oncol. 1996; 15:A770.

182. Omura GA, Brady MF, Delmore JE et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. Proc Annu Meet Am Soc Clin Oncol. 1996; 15:A755.

183. Spencer CM, Faulds D. Paclitaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs. 1994; 48:794-847. [PubMed 7530632]

184. Wiseman LR, Spencer CM. Paclitaxel: an update of its use in the treatment of metastatic breast cancer and ovarian and other gynecological cancers. Drugs Aging. 1998; 12:305-34. [PubMed 9571394]

185. Kearns CM. Pharmacokinetics of the taxanes. Pharmacotherapy. 1997; 17(5 Pt 2):105S-9S. [IDIS 392026] [PubMed 9322877]

186. Rowinsky EK, Donehower RC. Antimicrotubule agents. In: DeVita VT Jr, Hellman S, Rosenberg SA eds. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott- Raven Publishers; 1997:467-83.

187. Dorr RT. Pharmacology of the taxanes. Pharmacotherapy. 1997; 17(5 Part 2):96S-104S. [IDIS 392025] [PubMed 9322876]

188. Baker SD. Drug interactions with the taxanes. Pharmacotherapy. 1997; 17(5 Part 2):126S-132S. [IDIS 392028] [PubMed 9322879]

189. Trissel LA. Pharmaceutical properties of paclitaxel and their effects on preparation and administration. Pharmacotherapy. 1997; 17(5 Part 2):133S-139S. [IDIS 392029] [PubMed 9322880]

190. Chin A, Ramakrishnan RR, Yoshimura NN et al. Paclitaxel stability and compatibility in polyolefin containers. Ann Pharmacother. 1994; 28:35-6. [IDIS 324580] [PubMed 7907239]

191. Mazzo DJ, Nguyen-Huu JJ, Pagniez S et al. Compatibility of docetaxel and paclitaxel in intravenous solutions with polyvinyl chloride infusion materials. Am J Health-Syst Pharm. 1997; 54(5):566-9. [IDIS 381401] [PubMed 9066868]

192. Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of Taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm. 1993; 50:300-4. [IDIS 308931] [PubMed 8097617]

193. Xu Q, Trissel LA, Martinez JF. Stability of paclitaxel in 5% dextrose injection or 0.9% sodium chloride injection at 4, 22, or 32 degrees C. Am J Hosp Pharm. 1994; 51:3058-60. [IDIS 339826] [PubMed 7856626]

194. Trissel LA, Xu Q, Martinez JF. Compounding an extended-stability admixture of paclitaxel for long-term infusion. Int J Pharm Compound. 1997; 1(1):49-53.

195. Trissel LA, Xu Q, Kwan J et al. Compatibility of paclitabxel injection vehicle with intravenous administration and extension sets. Am J Hosp Pharm. 1994; 51:2804-10. [IDIS 338294] [PubMed 7856604]

196. Gianni L, Kearns CM, Giani A et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol. 1995; 13:180-90. [IDIS 340525] [PubMed 7799018]

197. Walle T, Walle UK, Kumar GN et al. Taxol metabolism and disposition in cancer patients. Drug Metab Dispos. 1995; 23:506-12. [IDIS 345569] [PubMed 7600920]

198. Ohtsu T, Sasaki Y, Tamura T et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res. 1995; 1(6):599-606. [IDIS 349299] [PubMed 9816021]

199. Glantz MJ, Choy H, Kearns CM et al. Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. J Natl Cancer Inst. 1995; 87(14):1077-81. [IDIS 352352] [PubMed 7616600]

200. Sonnichsen DS, Hurwitz CA, Pratt CB et al. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol. 1994; 12:532-8. [IDIS 327007] [PubMed 7907130]

201. Goldspiel BR. Clinical overview of the taxanes. Pharmacotherapy. 1997; 17(5 Part 2):110S-125S. [IDIS 392027] [PubMed 9322878]

202. Kivisto KT, Kroemer HK. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol. 1995; 40(6):523-30. [IDIS 358038] [PubMed 8703657]

203. Holmes FA, Madden T, Newman RA et al. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1996; 14(10):2713-21. [IDIS 373955] [PubMed 8874332]

204. Obasaju CK, Johnson SW, Rogatko A et al. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. Clin Cancer Res. 1996; 2(3):549-52. [IDIS 361787] [PubMed 9816202]

205. Monsarrat B, Alvinerie P, Wright M et al. Hepatic metabolism and biliary clearance of Taxol in rats and human. J Natl Cancer Inst Monogr. 1993; 15:39-46. [PubMed 7912528]

206. Bissery MC, Nohynek G, Sanderink G-J et al. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anti-Cancer Drugs. 1995; 6:339-68. [PubMed 7670132]

207. Vokes EE, Haraf DJ, Stenson K et al. The role of paclitaxel in the treatment of head and neck cancer. Semin Oncol. 1995; 22(Suppl 12):8-12. [PubMed 7481866]

208. Shin DM, Glisson BS, Khuri FR et al. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998; 16:1325-30. [IDIS 404221] [PubMed 9552033]

209. Fountzilas G, Athanassiades A, Kalogera-Fountzila A et al. Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck cancer. Semin Oncol. 1997; 24(6 Suppl 19):28-32.

210. Stathopoulos GP, Rigatos S, Papakostas P et al. Effectiveness of paclitaxel and carboplatin combination in heavily pretreated patients with head and neck cancers. Eur J Cancer. 1997; 33:1780-3. [PubMed 9470832]

211. Birch R, Weaver CH, Hainsworth JD et al. A randomized study of etoposide and carboplatin with or without paclitaxel in the treatment of small cell lung cancer. Semin Oncol. 1997; 24(Suppl 12):S135-7.

212. Shin DM, Glisson BS, Khuri FR et al. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol. 1997; 24(6 Suppl 19):33-7.

213. Schantz SP, Harrison LB, Forastiere AA. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. In: DeVita VT Jr, Hellman S, Rosenberg SA eds. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven Publishers; 1997:741-801.

214. Anon. Taxol/cisplatin first-line ovarian cancer indication clears FDA. F-D-C Rep. 1998 Apr 20.

215. Breast cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2006 Feb 14.

216. Welles L, Saville MW, Lietzau J et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi’s sarcoma. J Clin Oncol. 1998; 16:1112-21. [IDIS 402283] [PubMed 9508198]

217. Non-small cell lung cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2006 Mar 1.

218. Roa V, Conner A, Mitchell RB. Carboplatin and paclitaxel for previously treated patients with non-small-cell lung cancer. Cancer Invest. 1998; 16:381-4. [PubMed 9679528]

219. Ihde DC, Pfister DG, Baker S et al. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol. 1997; 15:2996-3018. [IDIS 391214] [PubMed 9256144]

220. Greco FA, Stroup SL, Gray JR et al. Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1996; 14:1642-8. [IDIS 366406] [PubMed 8622083]

221. Belani CP. Paclitaxel/carboplatin in the treatment of non-small-cell lung cancer. Oncology. 1998; 12:74-9. [PubMed 9516617]

222. Bonomi P, Kim K, Kusler J et al. Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer. Oncology. 1997(Apr); 11:9-10.

223. Choy H, Akerley W, Devore R. Paclitaxel, carboplatin and radiation therapy for non- small-cell lung cancer. Oncology. 1998; 12:80-6. [PubMed 9516618]

224. Redman BG, Smith DC, Flaherty L et al. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol. 1998; 16:1844-8. [IDIS 406126] [PubMed 9586899]

225. Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future. Clin Cancer Res. 1998; 4:1087-100. [IDIS 404414] [PubMed 9607565]

226. Ruckdeschel JC. Future directions in non-small-cell lung cancer: a continuing perspective. Oncology. 1998; 12:90-6. [PubMed 9516620]

227. Comis RL, Friedland DM, Good BC. Small-cell lung cancer: a perspective on the past and a preview of the future. Oncology. 1998; 12:44-50. [PubMed 9516611]

228. Smit EF, Fokkema E, Biesma B et al. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer. 1998; 77:347-51. [PubMed 9461009]

229. Hainsworth JD, Gray JR, Stroup SL et al. Paclitaxel, carboplatin, and extended- schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities. J Clin Oncol. 1997; 15:3464-70. [IDIS 397897] [PubMed 9396399]

230. Sonpavde G, Ansari R, Walker P et al. Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: a Hoosier Oncology Group Trial. Am J Clin Oncol. 2000; 23:68-70. [IDIS 441340] [PubMed 10683082]

231. Belani CP, Luketich JD, Landreaneau RJ et al. Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus. Semin Oncol. 1997; 24(6 Suppl 19):89-92.

232. Bladder cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2006 Apr 12.

233. Kosmidis P, Mylonakis N, Fountzilas G et al. Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) in non-small cell lung cancer: a randomized study. Semin Oncol. 1997; 24(4 Suppl 12):30-3.

234. Giaccone G, Splinter TAW, Debruyne C et al. Randomized study of paclitaxel- cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. J Clin Oncol. 1998; 16:2133-41. [IDIS 407442] [PubMed 9626213]

235. Perng R-P, Chen Y-M, Wu M-F et al. Phase II trial of intrapleural paclitaxel injection for non-small-cell lung cancer patients with malignant pleural effusions. Respir Med. 1998; 92:473-9. [PubMed 9692108]

236. Bishop JF, Dewar J, Tattersall MHN et al. Taxol alone is equivalent to CMFP combination chemotherapy as frontline treatment in metastatic breast cancer. Proc Am Soc Clin Oncol. 1997; 16:153a.

237. Bishop JF, Dewar J, Toner G et al. A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Semin Oncol. 1997; 24(5 Suppl 17):5-9.

238. Sledge Jr GW, Neuberg D, Ingle J et al. Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial. Proc Am Soc Clin Oncol. 1997; 16:1a.

239. ten Bokkel Huinink WW, van Warmerdam LJC, Helmerhorst TJ et al. Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer. Ann Oncol. 1997; 8:351-4. [PubMed 9209664]

240. Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000; 18:3084-92. [IDIS 452749] [PubMed 10963636]

241. Pectasides D, Papadopoulou M, Varthalitis J et al. Paclitaxel in cisplatin or carboplatin-pretreated ovarian cancer: phase II study. Oncology. 1998; 55:228-34. [PubMed 9560055]

242. Nardi M, Aloe A, De Marco S et al. Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study. Am J Clin Oncol. 1997; 20:230-2. [IDIS 387190] [PubMed 9167742]

243. Slichenmyer WJ, Donehower RC, Chen T-L et al. Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia. Cancer Chemother Pharmacol. 1995; 36:227-32. [PubMed 7781143]

244. Genentech, Inc. Herceptin (trastuzumab) prescribing information. San Francisco, CA; 1998 Sept.

245. Gamucci T, Piccart M, Brüning P et al. Single agent taxol (T) versus doxorubicin (D) as first-line chemotherapy (CT) in advanced breast cancer (ABC). Final results of an EORTC randomized study with crossover. Proc Am Soc Clin Oncol. 1998; 17:A428.

246. Eisenhauer EA, Vermorken JB. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs. 1998; 55:5-30. [PubMed 9463787]

247. Rose PG, Fusco N, Fluellen L et al. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol. 1998; 16:1494-7. [IDIS 404237] [PubMed 9552057]

248. Reviewers’ comments (personal observations) on bladder cancer.

249. du Bois A, Richter B, Warm M et al. Cisplatin/paclitaxel vs carboplatin/paclitaxel as first-line treatment in ovarian cancer. Proc Am Soc Clin Oncol. 1998; 17:Abstract 1395.

250. Markman M, Rose PG, Jones E et al. Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens. J Clin Oncol. 1998; 16:1849-51. [IDIS 406127] [PubMed 9586900]

251. Markman M, Brady MF, Spirtos NM et al. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol. 1998; 16:2620-4. [IDIS 410688] [PubMed 9704711]

252. Mamounas E, Brown A, Smith R et al. Effect of taxol duration of infusion in advanced breast cancer (ABC): results from NSABP-26 trial comparing 3- to 24-hr infusion of high-dose taxol. Proc Am Soc Clin Oncol. 1998; 17:Abstract 389.

253. Holmes FA, Valero V, Buzdar AU et al. Final results: randomized phase III trial of paclitaxel by 3-hr versus 96-hr infusion in patients (PT) with met breast cancer (MBC). The long & short of it. Proc Am Soc Clin Oncol. 1998; 17:Abstract 426.

254. Bonomi P, Kim K, Fairclough D et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000; 18:623-31. [IDIS 442904] [PubMed 10653877]

255. Millward MJ, Bishop JF, Friedlander M et al. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol. 1996; 14:142-8. [IDIS 358673] [PubMed 8558189]

256. Gatzemeier U, Heckmayr M, Neuhauss R et al. Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung Cancer. 1995; 12(Suppl 2):S101-6. [PubMed 7551941]

257. Hainsworth JD, Thompson DS, Greco FA. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol. 1995; 13:1609-14. [IDIS 349568] [PubMed 7602349]

258. Ruckdeschel J, Wagner H Jr, Williams C et al. Second-line chemotherapy for resistant, metastatic, non-small cell lung cancer (NSCLC): the role of taxol (TAX). Proc Am Soc Clin Oncol. 1994; 13:A1200.

259. Langer CJ, Leighton JC, Comis RL et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol. 1995; 13:1860-70. [IDIS 351040] [PubMed 7543559]

260. Forastiere AA, Leong T, Murphy B et al. A phase III trial of high-dose paclitaxel + cisplatin + G-CSF versus low-dose paclitaxel + cisplatin in patients with advanced squamous cell carcinoma of the head and neck (HNSCC): an Eastern Cooperative Oncology Group trial. Proc Am Soc Clin Oncol. 1997; 16:A1367.

261. McWilliams JE, Cohen JI, Everts EC et al. A phase II trial of lower dose paclitaxel in recurrent and metastatic head and neck squamous cell carcinoma (HNSCC). Proc Am Soc Clin Oncol. 1998; 17:Abstract 1570.

262. Vermorken JB, Catimel G, Stupp R et al. Randomized phase II trial of methotrexate (MTX) versus two schedules of Taxol (T) in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol. 1997; 16:A1463.

263. Bristol-Myers Squibb. Taxol (paclitaxel) for injection concentrate formulary guide. Princeton, NJ; 1994 Apr. Publication K4-B043.

264. Newton DW. Introduction: physicochemical determinants of incompatibility and instability drugs for injection and infusion. In: Trissel LA. Handbook on injectable drugs. 3rd ed. Bethesda, MD: American Society of Hospital Pharmacists, Inc; 1983.

265. Wiernik PH, Schwartz EL, Strauman JJ et al. Phase I clinical and pharmacokinetic study of taxol. Cancer Res. 1987; 47:2486-93. [IDIS 229678] [PubMed 2882837]

266. Bolis G, Colombo N, Pecorelli S et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol. 1995; 6:887-93. [PubMed 8624291]

267. Winer E, Berry D, Duggan D et al. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer—results from CALGB 9342. Proc Am Soc Clin Oncol. 1998; 17:A388.

268. Seidman AD, Hudis CA, Albanel J et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol. 1998; 16:3353-51. [IDIS 414062] [PubMed 9779712]

269. Choy H, Akerley W, Safran H et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small cell lung cancer. J Clin Oncol. 1998; 16:3316-22. [IDIS 414057] [PubMed 9779707]

270. Thomas GM. Improved treatment for cervical cancer—concurrent chemotherapy and radiotherapy. N Engl J Med. 1999; 340:1198-1200. [IDIS 423015] [PubMed 10202172]

271. Cervical cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2006 Apr 12.

272. National Cancer Institute (NCI). Questions & answers: concurrent chemotherapy and radiation for cervical cancer. 1999 Feb 23.

273. McGuire WP, Blessing JA, Moore D et al. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol. 1996; 14:792-5. [IDIS 361931] [PubMed 8622025]

274. Kudelka AP, Winn R, Edwards CL et al. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs. 1997; 8:657-61. [PubMed 9311440]

275. Thigpen T, Vance RB, Khansur T. The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix. Semin Oncol. 1995; 22(5 Suppl 12):67-75. [PubMed 7481864]

276. Papadimitriou CA, Sarris K, Moulopoulos LA et al. Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. J Clin Oncol. 1999; 17:761-6. [IDIS 425398] [PubMed 10071264]

277. Reviewers’ comments (personal observations) on cervical cancer.

278. Eifel PJ. Concurrent chemotherapy and radiation: a major advance for women with cervical cancer. J Clin Oncol. 1999; 17:1334-5. [IDIS 428329] [PubMed 10334515]

279. Rose PG, Blessing JA, Gershenson DM et al. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 1999; 17:2676-80. [IDIS 435270] [PubMed 10561341]

280. Piver MS, Ghamande SA, Eltabbakh GH et al. First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix—a phase II study. Gynecol Oncol. 1999; 75:334-7. [PubMed 10600285]

281. UDL Laboratories, Inc. Paclitaxel injection prescribing information. Rockford, IL; 2001 Jun.

282. Food and Drug Administration. Sulfites in foods and drugs. FDA Drug Bull. 1983; 13:12. [PubMed 6604672]

283. Sogn D. The ubiquitous sulfites. JAMA. 1984; 251:2986-7. [IDIS 185969] [PubMed 6716628]

284. Koepke JW, Christopher KL, Chai H et al. Dose-dependent bronchospasm from sulfites in isoetharine. JAMA. 1984; 251:2982-3. [IDIS 185966] [PubMed 6716626]

285. Twarog FJ, Leung DYM. Anaphylaxis to a component of isoetharine (sodium bisulfite). JAMA. 1982; 248:2030-1. [IDIS 158261] [PubMed 7120631]

286. Baker GJ, Collett P, Allen DH. Bronchospasm induced by metabisulphite-containing foods and drugs. Med J Aust. 1981; 2:614-7. [IDIS 146240] [PubMed 7334982]

287. Koepke JW, Selner JC, Dunhill AL. Presence of sulfur dioxide in commonly used bronchodilator solutions. J Allergy Clin Immunol. 1983; 72:504-8. [IDIS 178793] [PubMed 6630799]

288. Food and Drug Administration. Sulfiting agents; labeling in drugs for human use: warning statement. [Docket No. 84N-0113] Fed Regist. 1985; 50:47558-63.

289. Food and Drug Administration Center for Food Safety and Applied Nutrition. The reexamination of the GRAS status of sulfiting agents, January 1985. (Doc. No. 223-83-2020.) Bethesda, MD: FASEB Life Sciences Research Office.

290. FDA advise-ERR: medication errors associated with Taxotere and Taxol. Rockville, MD: US Food and Drug Administration; 2001 Feb 7.

291. Schiller JH, Harrington D, Sandler A et al. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 2000; 19:A2.

292. Kelly K, Crowley J, Bunn PA Jr et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001; 19:3210-8. [IDIS 466971] [PubMed 11432888]

293. Young RC, protocol chair. Phase III randomized study of CBDCA/TAX administered for 3 vs 6 courses for selected stages IA-C and stages IIA-C ovarian epithelial cancer. Protocol ID: GOG-157. Last modified: 11/4/2005. National Cancer Institute: Clinical Trials (database).

294. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003; 21:3194-200. [IDIS 505744] [PubMed 12860964]

295. Piccart MJ, Bertelsen K, Stuart G et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer. 2003; 13 Suppl 2:144-8. [PubMed 14656271]

296. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006; 354:34-43. [PubMed 16394300]

297. Cannistra SA. Intraperitoneal chemotherapy comes of age. N Engl J Med. 2006; 354:77-9. [PubMed 16394306]

298. Spriggs DR, Brady M, Rubin S et al. A phase III randomized trial of cisplatin and paclitaxel administered by either 24 hour or 96 hour infusion in patients with selected stage III or stage IV epithelial ovarian cancer (GOG162). Proc ASCO. 2004; Abstract No. 5004.

299. Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003; 21:2460-5. [PubMed 12829663]

300. Ozols RF. Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit. J Clin Oncol. 2003; 21:2451-3. [PubMed 12829660]

301. Thigpen T. Maybe more is better. J Clin Oncol. 2003; 21:2454-6. [PubMed 12829661]

302. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003; 361:2099-106. [IDIS 499619] [PubMed 12826431]

303. Goldberg JM, Piver MS, Hempling RE et al. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer. Gynecol Oncol. 1996; 63:312-7. [PubMed 8946864]

304. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003; 21:976-83. [PubMed 12637460]

305. Mamounas EP, Bryant J, Lembersky B et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005; 23:3686-96. [PubMed 15897552]

306. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003; 21:1431-9. [PubMed 12668651]

307. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353:1673-84. [IDIS 541600] [PubMed 16236738]

308. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353:1659-72. [PubMed 16236737]

309. Jassem J, Pienkowski T, Pluzanska A et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol. 2001; 19:1707-15. [PubMed 11251000]

310. Biganzoli L, Cufer T, Bruning P et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol. 2002; 20:3114-21. [PubMed 12118025]

311. Strauss GM, Herndon J, Maddaus MA et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633. Proc ASCO. 2004; Abstract No. 7019.

312. Hotta K, Matsuo K, Ueoka H et al. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol. 2004; 22:3860-7. [PubMed 15326194]

313. Belani CP, Larocca RV, Rinaldi DA et al. A multicenter, phase III randomized trial for stage IIIB/IV NSCLC of weekly paclitaxel and carboplatin vs. standard paclitaxel and carboplatin given every three weeks, followed by weekly paclitaxel. Proc ASCO. 2004; Abstract No. 7017.

314. Kosmidis P, Mylonakis N, Nicolaides C et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol. 2002; 20:3578-85. [PubMed 12202657]

315. Rosell R, Gatzemeier U, Betticher DC et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol. 2002; 13:1539-49. [PubMed 12377641]

316. Soria JC, Le Chevalier T. Is cisplatin still the best platinum compound in non-small-cell lung cancer? Ann Oncol. 2002; 13:1515-7.

317. Glisson BS, Kurie JM, Perez-Soler R et al. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J Clin Oncol. 1999; 17:2309-15. [PubMed 10561292]

318. Niell HB, Herndon JE 2nd, Miller AA et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B trial 9732. J Clin Oncol. 2005; 23:3752-9. [PubMed 15923572]

319. Mavroudis D, Papadakis E, Veslemes M et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol. 2001; 12:463-70. [PubMed 11398877]

320. Ettinger DS, Berkey BA, Abrams RA et al. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study. J Clin Oncol. 2005; 23:4991-8. [PubMed 15939930]

321. Urba SG, Orringer MB, Ianettonni M et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer. 2003; 98:2177-83. [PubMed 14601087]

322. Vaughn DJ, Broome CM, Hussain M et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol. 2002; 20:937-40. [PubMed 11844814]

323. Small EJ, Lew D, Redman BG et al. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol. 2000; 18:2537-44. [PubMed 10893284]

324. Vaishampayan UN, Faulkner JR, Small EJ et al. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study. Cancer. 2005; 104:1627-32. [PubMed 16138364]

325. Vaughn DJ, Manola J, Dreicer R et al. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. Cancer. 2002; 95:1022-7. [PubMed 12209686]

326. Johannsen M, Sachs M, Roigas J et al. Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer. Eur Urol. 2005; 48:246-51. [PubMed 15963636]

327. Dreicer R, Manola J, Roth BJ et al. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 2000; 18:1058-61. [PubMed 10694557]

328. Meluch AA, Greco FA, Burris HA 3rd et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2001; 19:3018-24. [PubMed 11408496]

329. Sternberg CN, Calabro F, Pizzocaro G et al. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer. 2001; 92:2993-8. [PubMed 11753976]

330. Gibson MK, Li Y, Murphy B et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005; 23:3562-7. [PubMed 15908667]

331. Langer CJ, Li Y, Jennings T et al. Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group. Cancer Invest. 2004; 22:823-31. [PubMed 15641479]

332. Garden AS, Harris J, Vokes EE et al. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol. 2004; 22:2856-64. [PubMed 15254053]

333. Hitt R, Lopez-Pousa A, Martinez-Trufero J et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005; 23:8636-45. [PubMed 16275937]

334. Curtin JP, Blessing JA, Webster KD et al. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2001; 19:1275-8. [PubMed 11230468]

335. Moore DH, Blessing JA, McQuellon RP et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2004; 22:3113-9. [PubMed 15284262]

336. Endometrial cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2006 May 11.

337. Ball HG, Blessing JA, Lentz SS et al. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1996; 62:278-81. [PubMed 8751561]

338. Lincoln S, Blessing JA, Lee RB et al. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003; 88:277-81. [PubMed 12648575]

339. Hoskins PJ, Swenerton KD, Pike JA et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol. 2001; 19:4048-53. [PubMed 11600606]

340. Fleming GF, Filiaci VL, Bentley RC et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol. 2004; 15:1173-8. [PubMed 15277255]

341. Fleming GF, Brunetto VL, Cella D et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004; 22:2159-66. [PubMed 15169803]

342. Miller D, protocol chair. Phase III randomized study of doxorubicin, cisplatin, paclitaxel, and filgrastim (G-CSF) versus carboplatin and paclitaxel in patients with stage III or IV or recurrent endometrial cancer. Protocol ID: GOG-0209. Last modified: 5/19/2006. National Cancer Institute: Clinical Trials (database).

343. Greven K, Winter K, Underhill K et al. Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer. Int J Radiat Oncol Biol Phys. 2004; 59:168-73. [PubMed 15093913]

344. Walker JL, Armstrong DK, Huang HQ et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006; 100:27-32. [PubMed 16368440]

345. Trimble EL, Christian MC. Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma. Gynecol Oncol. 2006; 100:3-4. [PubMed 16368439]

346. National Cancer Institute (NCI). NCI issues clinical announcement for preferred method of treatment for advanced ovarian cancer: questions and answers (January 4, 2006). From NCI web site.

347. National Cancer Institute (NCI). NCI clinical announcement on intraperitoneal chemotherapy in ovarian cancer (January 5, 2006). From NCI web site.

348. Piccart-Gebhart MJ. Mathematics and oncology: a match for life? J Clin Oncol. 2003; 21:1425-8.

349. Perez EA, Vogel CL, Irwin DH et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2001; 19:4216-23. [PubMed 11709565]

350. Spazzapan S, Crivellari D, Lombardi D et al. Nail toxicity related to weekly taxanes: an important issue requiring a change in common toxicity criteria grading? J Clin Oncol. 2002; 20:4404-5.

351. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344:783-92. [IDIS 461125] [PubMed 11248153]

352. Eli Lilly and Company. Gemzar (gemcitabine) prescribing information. Indianapolis, IN: 2006 Apr 5.

353. Albain KS, Nag S, Calderillo-Ruiz G et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. Proc ASCO. 2004; Abstract No. 510.

354. Celgene. Abraxane for injectable suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) prescribing information. Summit, NJ: 2013 Oct.

355. Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005; 23:7794-803. [PubMed 16172456]

356. Ibrahim NK, Samuels B, Page R et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol. 2005; 23:6019-26. [PubMed 16135470]

357. Desai N, Trieu V, Yao Z et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006; 12:1317-24. [PubMed 16489089]

358. Socinski MA, Bondarenko I, Karaseva NA et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012; 30:2055-62. [PubMed 22547591]

359. Azzoli CG, Temin S, Aliff T et al. 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol. 2011; 29:3825-31. [PubMed 21900105]

360. Satouchi M, Okamoto I, Sakai H et al. Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2013; 81:97-101. [PubMed 23545279]

361. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369:1691-703. [PubMed 24131140]

362. Pfizer Labs. Paclitaxel injection prescribing information. New York, NY: 2011 Jun.

363. Socinski MA, Evans T, Gettinger S et al. Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl):e341S-68S. [PubMed 23649446]

364. Biakhov MY, Kononova GV, Iglesias J et al. nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study. Expert Opin Drug Saf. 2010; 9:515-23. [PubMed 20500029]

HID. Trissel LA. Handbook on injectable drugs. 17th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2013:891-7.

Hide
(web2)